Lymphoma Clinical Trials in San Antonio

Showing 381-400 of 444 trials

Study of YM155 in Refractory Diffuse Large B-cell Lymphoma (DLBCL) Subjects

NCT00498914

A study in subjects with a type of B cell lymphoma (DLBCL)to evaluate the response rate, efficacy, safety and tolerability of YM155

Lymphoma, Large-Cell, DiffuseLymphoma, B-Cell Refractory

Astellas Pharma Inc41 participantsStarted Jun 2007

Beverly Hills, California, United States • Palo Alto, California, United States • Aurora, Colorado, United States +19 more locations

COMPLETEDPhase 1< 1 mile

Safety Study of AP23573 in Patients With Advanced, Refractory or Recurrent Malignancies (8669-013)(COMPLETED)

NCT00060645

Phase 1 trial to determine the safety, tolerability and maximum tolerated dose (MTD) of AP23573 in patients with refractory or recurrent malignancies, including myeloma and lymphoma.

TumorsLymphomaMultiple Myeloma

Merck Sharp & Dohme LLC33 participantsStarted May 2003

San Antonio, Texas, United States

COMPLETEDPhase 1< 1 mile

Dasatinib in Treating Patients With Solid Tumors or Lymphomas That Are Metastatic or Cannot Be Removed By Surgery

NCT00608361

This phase I trial studies the side effects and best dose of dasatinib in treating patients with solid tumors or lymphomas that are metastatic or cannot be removed by surgery. Dasatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

Adult Acute Lymphoblastic Leukemia in RemissionAdult B Acute Lymphoblastic LeukemiaAdult Hepatocellular Carcinoma+82 more

National Cancer Institute (NCI)80 participantsStarted Oct 2008

Duarte, California, United States • Los Angeles, California, United States • Los Angeles, California, United States +20 more locations

Study of YM155 in Refractory Diffuse Large B-cell Lymphoma (DLBCL) Subjects

Safety Study of AP23573 in Patients With Advanced, Refractory or Recurrent Malignancies (8669-013)(COMPLETED)

Dasatinib in Treating Patients With Solid Tumors or Lymphomas That Are Metastatic or Cannot Be Removed By Surgery

Lymphoma Trials in Other Cities

Phase I/II Study of CAMPATH in Patients With Relapsing or Refractory Non-Hodgkin's Lymphoma

Dosing and Safety Study of E7820 in Patients With a Malignant Solid Tumor or Lymphoma

Combination Chemotherapy With or Without Dexrazoxane in Treating Children With Hodgkin's Disease

Vorinostat in Treating Patients With Relapsed or Refractory Advanced Hodgkin's Lymphoma

Study Evaluating Temsirolimus (CCI-779) In Mantle Cell Lymphoma (MCL)

Safety and Activity of SDX-105 (Bendamustine) in Patients With Rituximab Refractory Non-Hodgkin's Lymphoma

A Phase II Clinical Trial of PXD101 in Patients With Recurrent or Refractory Cutaneous and Peripheral T-Cell Lymphomas

MGCD0103 Administered in Combination With Azacitidine (Vidaza®) to Subjects With Relapsed or Refractory Hodgkin or Non-Hodgkin Lymphoma

A Randomized Phase IIb Placebo-Controlled Study of R-ICE Chemotherapy With and Without SGN-40 for Patients With DLBCL

Allo BMT Using Matched Related/Unrelated Donors With FluBu and HiCY

A Phase I Dose Escalation Study of SGN-35 Alone and in Combination With Gemcitabine for CD30-Positive Malignancies

A Safety Study of SGN-40 in Patients With Non-Hodgkin's Lymphoma

GAUSS: A Study of Obinutuzumab (RO5072759) in Patients With Indolent Non-Hodgkin's Lymphoma

Cardiac Safety Study of Brentuximab Vedotin (SGN-35)

S0350 Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Peripheral T-Cell Non-Hodgkin's Lymphoma

Safety and Tolerability Study of SNS01-T in Relapsed or Refractory B Cell Malignancies (Multiple Myeloma, B Cell Lymphoma, or Plasma Cell Leukemia (PCL)

Comparative Trial for Pixantrone in Combination With Rituximab in Indolent Non-Hodgkin's Lymphoma

Other Conditions in San Antonio